International Journal of Cancer · 2019 · 12 citations · 23 references
MedicineOncologyPharmacologyBreast OncologyMetastasisMolecular OncologyBreast Cancer OncologyCancer ImmunotherapyHer2-positive Breast CancerHormonal Cancer TherapyHormonal TherapyMetastatic Breast CancerBreast Cancer Molecular SubtypesHer2-positive Breast Cancer ImmunotherapyHer2-positive Breast Cancer TherapyHer2-positive Metastatic DiseaseHuman Epidermal Growth Factor Receptor 2-Targeted TherapyMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast CancerPertuzumab Therapy
We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival at first-line (mPFS1) was 12 months. Pertuzumab as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T-DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs; p = 0.17), while a trend emerged for tumors with one HR (p = 0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p = 0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T-DM1 in second-line after pertuzumab were significantly lower compared to pertuzumab-naïve patients (p = 0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p = 0.02 and p = 0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-related outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor pathways in HER2-positive (mbc) patients.
23
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.8K citations · Full text
Medicine, Oncology, Pharmacology +14
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +12
Metastatic Behavior of Breast Cancer Subtypes
Hagen F. Kennecke, Rinat Yerushalmi, Ryan Woods et al. · Journal of Clinical Oncology · 2010 · 2.3K citations · Full text
Medicine, Cancer Biology, Oncology +14
Sandra M. Swain, Sung‐Bae Kim, Javier Cortés et al. · The Lancet Oncology · 2013 · 1K citations · Full text
Medicine, Oncology, Pharmacology +16